[The Keyrole of Multiomics in the Predictive, Preventive and Personalised Medical Approach towards Glaucoma Management].

Glaucoma is the second leading cause of blindness, with altogether about 70 million patients registered worldwide. These facts prompt us to reconsider currently applied concepts in overall glaucoma management. Innovative strategies of predictive, preventive and personalised medicine (PPPM) are expected to considerably improve disease prevention and personalised treatment. The comprehensive PPPM measures include the application of individualised patient profiles, "phenotyping", molecular characterisation of the pre-lesions and disease stages, innovative screening programs, patient stratification, early and predictive diagnosis, targeted prevention, and the creation of personalised treatment algorithms. The main stakeholders are glaucoma-dedicated researchers, ophthalmologists, general practitioners, groups at risk, specialised medical units, affected patients and their family members, insurances, policy makers, and the diagnostic and pharmaceutical industries. Potential beneficiaries include these groups as well as society as a whole, due to financial savings in the healthcare expected.